Jaguar Health Inc (JAGX)

[Viewmont]

Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16
ACCESSWIRE ACCESSWIRE•September 11, 2020
SAN FRANCISCO, CA / ACCESSWIRE / September 11, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte, Jaguar's founder, president and CEO, will present at the virtual 2020 H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020, at 3:00 p.m. Eastern Time. Ms. Conte will be available to participate in virtual one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor and would like to attend the Jaguar presentation, please visit www.hcwevents.com to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website, where you can request a one-on-one meeting with Jaguar.

Conference Details

Event: H.C. Wainwright 22nd Annual Global Investment Conference
Conference Dates: September 14-16, 2020
Jaguar Presentation Time: 3:00 p.m. Eastern Time on Wednesday, September 16, 2020
Location: Virtual Conference

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.